<?xml version="1.0" encoding="UTF-8"?>
<jcr:root xmlns:jcr="http://www.jcp.org/jcr/1.0" xmlns:nt="http://www.jcp.org/jcr/nt/1.0" xmlns:mix="http://www.jcp.org/jcr/mix/1.0" xmlns:cq="http://www.day.com/jcr/cq/1.0" xmlns:sling="http://sling.apache.org/jcr/sling/1.0"
    jcr:primaryType="cq:Page">
    <jcr:content
        cq:lastModified="{Date}2024-02-08T16:27:44.859Z"
        cq:lastModifiedBy="reference-adjustment-service"
        cq:template="/conf/menarini-berlinchemie/settings/wcm/templates/menarini---details-news"
        jcr:isCheckedOut="{Boolean}true"
        jcr:mixinTypes="[mix:versionable]"
        jcr:primaryType="cq:PageContent"
        jcr:title="ESMO Annual Meeting 2019: Menarini Ricerche presents the preclinical characterization of MEN1611, a novel PI3K inhibitor in development for the treatm"
        jcr:uuid="eadbb9c9-eb26-4d25-ac16-112c912820d7"
        sling:resourceType="menarinimaster/components/page"
        dnnNewsIdentifier="8a1c191b-1720-40aa-88de-c68d8076ed34-912">
        <root
            jcr:primaryType="nt:unstructured"
            sling:resourceType="menarinimaster/components/container"
            layout="responsiveGrid">
            <container
                jcr:primaryType="nt:unstructured"
                sling:resourceType="menarinimaster/components/container"
                layout="responsiveGrid">
                <internalheader
                    jcr:primaryType="nt:unstructured"
                    jcr:title="News &amp; Medien"
                    sling:resourceType="menarinimaster/components/internalheader"
                    altValueFromDAM="{Boolean}false"
                    imageFromPageImage="{Boolean}false"
                    titleFromPage="{Boolean}false"/>
                <section
                    jcr:lastModified="{Date}2023-05-23T15:09:53.441Z"
                    jcr:lastModifiedBy="a.messori@adiacent.com"
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/section">
                    <wrapper
                        jcr:lastModified="{Date}2023-05-23T15:11:01.995Z"
                        jcr:lastModifiedBy="a.messori@adiacent.com"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/wrapper">
                        <breadcrumb
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/breadcrumb"/>
                    </wrapper>
                </section>
                <container
                    jcr:primaryType="nt:unstructured"
                    sling:resourceType="menarinimaster/components/container"
                    layout="responsiveGrid">
                    <internalmenu
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/internalmenu"
                        navigationRoot="/content/menarini-berlinchemie/de/menarini-group-news"
                        structureStart="{Long}0">
                        <cq:responsive jcr:primaryType="nt:unstructured">
                            <default
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="3"/>
                            <tablet
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="4"/>
                            <phone
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </internalmenu>
                    <container
                        cq:styleIds="[1684742346871]"
                        jcr:primaryType="nt:unstructured"
                        sling:resourceType="menarinimaster/components/container"
                        layout="responsiveGrid">
                        <news_data
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/news_data"
                            newsDate="{Date}2019-09-23T08:30:00.000Z">
                            <cq:responsive jcr:primaryType="nt:unstructured">
                                <default
                                    jcr:primaryType="nt:unstructured"
                                    offset="0"
                                    width="9"/>
                            </cq:responsive>
                        </news_data>
                        <title
                            cq:styleIds="[1653552493699]"
                            jcr:lastModified="{Date}2023-06-07T15:16:13.835Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/title"
                            linkTarget="_self"
                            type="h2"/>
                        <image
                            jcr:lastModified="{Long}1707398379169"
                            jcr:lastModifiedBy="Importer"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/image"
                            displayPopupTitle="true"
                            fileReference="/content/dam/menarini-berlinchemie/assets/news/img-INTRO-Menarini-Ricerche_per_news.jpg"
                            imageFromPageImage="{Boolean}false"
                            isDecorative="true"
                            linkTarget="_self"
                            titleValueFromDAM="false">
                            <cq:responsive jcr:primaryType="nt:unstructured">
                                <default
                                    jcr:primaryType="nt:unstructured"
                                    offset="2"
                                    width="4"/>
                                <phone
                                    jcr:primaryType="nt:unstructured"
                                    offset="1"
                                    width="10"/>
                            </cq:responsive>
                        </image>
                        <spacer
                            jcr:lastModified="{Date}2023-06-07T15:17:27.212Z"
                            jcr:lastModifiedBy="d.mariotti@adiacent.com"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/spacer"
                            spacer="40"/>
                        <text
                            jcr:lastModified="{Long}1707398379172"
                            jcr:lastModifiedBy="Importer"
                            jcr:primaryType="nt:unstructured"
                            sling:resourceType="menarinimaster/components/text"
                            text="&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: center;&quot;>&lt;strong>&lt;span>&lt;img alt=&quot;&quot; src=&quot;/Portals/31/Images/notizie/Menarini-Ricerche.jpg?ver=2017-06-07-155706-953&quot; style=&quot;text-align: center;&quot; />&lt;/span>&lt;/strong>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: center;&quot;>&amp;nbsp;&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: justify;&quot;>&lt;strong>&lt;span>Pomezia (Italy) September 23&lt;sup>rd&lt;/sup>, 2019&lt;/span>&lt;/strong>&lt;span> &amp;ndash; Promising results from the &lt;/span>&lt;span>preclinical study conducted by Menarini Ricerche on &lt;a href=&quot;https://www.menarini.it/Home/Innovazione-Ricerca/MEN1611&quot;>MEN1611&lt;/a>, a potent and selective orally available phosphatidylinositol 3-kinase (PI3K) inhibitor currently in development &lt;/span>&lt;span>for the treatment of breast cancer. The poster entitled &lt;/span>&lt;span>&amp;ldquo;&lt;/span>&lt;em>&lt;span>Characterization of the mechanism of action and efficacy of MEN1611, a novel PI3K inhibitor, in breast cancer preclinical models&lt;/span>&lt;/em>&lt;span>&amp;rdquo; will be presented at &lt;/span>&lt;span>the ESMO Annual Meeting 2019, which will take place in Barcelona on September 27&lt;sup>th&lt;/sup>, during the poster display session scheduled on September 30&lt;sup>th&lt;/sup> (time 12-13).&lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: justify;&quot;>&lt;span>&amp;nbsp;&lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: justify;&quot;>&lt;span style=&quot;color: black; background: white;&quot;>The PI3K/AKT &lt;/span>&lt;span>signaling &lt;/span>&lt;span style=&quot;color: black; background: white;&quot;>pathway is often dysregulated in patients with cancer: a&lt;/span>&lt;span>bout 25% of HER2-positive breast cancers carry PIK3CA gene mutations, known to confer resistance to anti-HER2 therapy (&lt;em>i.e&lt;/em>. trastuzumab). This study, conducted &lt;/span>&lt;span>in several HER2-positive PIK3CA-mutated breast cancer cell lines and patient-derived xenograft models,&lt;/span>&lt;span> shows that &lt;/span>&lt;strong>&lt;span>MEN1611 is able to down-modulate the PI3K/AKT pathway&lt;/span>&lt;/strong>&lt;span> both &lt;em>in vitro&lt;/em> and &lt;em>in vivo,&lt;/em> and &lt;strong>acts synergistically when combined with trastuzumab&lt;/strong>; moreover, the &lt;strong>&lt;em>in vivo&lt;/em> efficacy in trastuzumab-resistant models&lt;/strong> is demonstrated by a &lt;strong>long lasting antitumor activity&lt;/strong>. &lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: justify;&quot;>&lt;span>These promising preclinical data, provide a strong rationale for MEN 1611 progression in clinical development &lt;/span>&lt;span>in breast cancer patients&lt;/span>&lt;span>. &amp;nbsp;&lt;/span>&lt;span>In this regard, the &lt;strong>B-Precise-01 clinical trial&lt;/strong> &lt;/span>&lt;span>(NCT&lt;span style=&quot;background: white;&quot;>03767335&lt;/span>)&lt;/span>&lt;span>, a multicentre phase Ib study, is&lt;/span>&lt;span> currently ongoing in Europe with the aim &lt;/span>&lt;span>to evaluate the preliminary clinical activity of &lt;a href=&quot;https://www.menarini.it/Home/Innovazione-Ricerca/MEN1611&quot;>MEN1611&lt;/a> in combination with trastuzumab +/- fulvestrant, in &lt;/span>&lt;span>patients affected by advanced or metastatic HER2-positive breast cancer, and &lt;/span>&lt;span>to select the recommended &lt;/span>&lt;span>phase 2 dose&lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: justify;&quot;>&lt;span>This year Menarini Ricerche will be present at ESMO congress also with a dedicated area at the &lt;strong>&lt;a href=&quot;https://www.menarini.it/Admin/Gestione-articoli-Comunica-Dettaglio-Multilingua/ctl/Edit/ArticleID/2610/mid/6571/lng/www.siliconbiosystems.com/&quot; target=&quot;_blank&quot;>Menarini&lt;/a>&lt;/strong>&lt;strong>&lt;a href=&quot;https://www.menarini.it/Admin/Gestione-articoli-Comunica-Dettaglio-Multilingua/ctl/Edit/ArticleID/2610/mid/6571/lng/www.siliconbiosystems.com/&quot; target=&quot;_blank&quot;>Silicon Biosystems&lt;/a> booth&lt;/strong>, where it will be possible to get more detailed information about the entire Menarini oncology pipeline and the ongoing clinical trials. Indeed, MEN1611 is part of an innovative pipeline of investigational new drugs focused on &lt;/span>&lt;strong>&lt;span>precision medicine approaches&lt;/span>&lt;/strong>&lt;span>, that represents the &lt;/span>&lt;span>strong and growing commitment of Menarini to oncology&lt;/span>&lt;span> &lt;/span>&lt;span>and to patients affected by difficult to treat cancers.&lt;/span>&lt;/p>&#xa;&#xa;&lt;p style=&quot;margin-bottom: 0.0001pt; text-align: justify;&quot;>&lt;span style=&quot;color: red;&quot;>&amp;nbsp;&lt;/span>&lt;/p>&#xa;&#xa;&lt;p>&lt;span>&amp;nbsp;&lt;/span>&lt;/p>"
                            textIsRich="true"/>
                        <cq:responsive jcr:primaryType="nt:unstructured">
                            <default
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <tablet
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="8"/>
                            <phone
                                jcr:primaryType="nt:unstructured"
                                offset="0"
                                width="12"/>
                        </cq:responsive>
                    </container>
                </container>
            </container>
        </root>
        <cq:featuredimage
            jcr:primaryType="nt:unstructured"
            sling:resourceType="core/wcm/components/image/v3/image"
            altValueFromDAM="{Boolean}false"
            fileReference="/content/dam/menarini-berlinchemie/assets/news/img-INTRO-Menarini-Ricerche_per_news.jpg"/>
    </jcr:content>
</jcr:root>
